Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation BTK inhibitor.
The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.